<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002353</url>
  </required_header>
  <id_info>
    <org_study_id>090</org_study_id>
    <secondary_id>V103B</secondary_id>
    <nct_id>NCT00002353</nct_id>
  </id_info>
  <brief_title>A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects</brief_title>
  <official_title>A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate an HIV lipopeptide immunotherapeutic, P3C541b, at two dose levels administered&#xD;
      subcutaneously in HIV-seropositive patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive P3C541b or placebo within each of two study groups.&#xD;
      Enrollment in the first group will be independent of HLA type, whereas all but two of the&#xD;
      patients enrolled in group 2 must have one or more HLA types A33, B8, B27, or Bw62. Treatment&#xD;
      in group 2 will not begin until those in group 1 have reached day 14 without serious&#xD;
      toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P3C541b Lipopeptide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV positivity.&#xD;
&#xD;
          -  CD4 count &gt;= 500 cells/mm3.&#xD;
&#xD;
          -  No evidence of AIDS, persistent diarrhea, fever, oral hairy leukoplakia, herpes&#xD;
             varicella-zoster (multidermatomal), oral candidiasis, opportunistic infections, severe&#xD;
             cytomegalovirus infection, or disseminated or chronic herpes simplex.&#xD;
&#xD;
          -  Successful establishment of EBV transformed B lymphoblastoid cell line.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Most patients in group 2 must possess one or more HLA types A33, B8, B27, or Bw62.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Active syphilis.&#xD;
&#xD;
          -  Positive circulating hepatitis B virus antigen.&#xD;
&#xD;
          -  Active clinically significant medical problems.&#xD;
&#xD;
          -  Evidence of psychiatric, medical, or substance abuse problems that would affect&#xD;
             ability to participate on study.&#xD;
&#xD;
          -  Occupational or other responsibilities that would prevent completion of study.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other HIV immunotherapeutic.&#xD;
&#xD;
          -  Zidovudine or analog.&#xD;
&#xD;
          -  Investigational therapies for HIV.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of cancer unless surgically excised with reasonable assurance of cure.&#xD;
&#xD;
          -  History of anaphylaxis or other serious adverse reactions to vaccines.&#xD;
&#xD;
          -  History of serious allergic reaction to any substance that required hospitalization or&#xD;
             emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasms, or hypotension).&#xD;
&#xD;
          -  History of autoimmune disease or use of immunosuppressive medications.&#xD;
&#xD;
          -  History of suicide attempts or past psychosis.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within the past 6 months:&#xD;
&#xD;
          -  HIV immunotherapeutic.&#xD;
&#xD;
          -  Zidovudine or analog.&#xD;
&#xD;
          -  Investigational therapies for HIV. Illicit drug use within past 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beth Israel Hosp</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 1997</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Vaccines, Synthetic</keyword>
  <keyword>AIDS Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

